SGLT2 Inhibitors and Safety in Older Patients.
Heart Fail Clin
; 18(4): 635-643, 2022 Oct.
Article
em En
| MEDLINE
| ID: mdl-36216492
ABSTRACT
SGLT2 inhibitors (SGLT2i) are effective in the management of diabetes and in reducing adverse cardiovascular and renal outcomes. Randomized clinical trials demonstrated safety and tolerability in older adults. Adverse effects associated with SGLT2i are impacted by patient frailty, comorbidities, and concomitant medication use and, therefore, must be thoroughly evaluated before initiating treatment. The risk of volume depletion, hypoglycemia, genital infections, and diabetic ketoacidosis can be minimized by appropriate patient selection, patient education, and early symptom recognition. Limited data exists regarding the risk of urinary tract infections, fractures, and amputations in the elderly treated with SGLT2i and routine monitoring is recommended.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cetoacidose Diabética
/
Diabetes Mellitus Tipo 2
/
Inibidores do Transportador 2 de Sódio-Glicose
/
Hipoglicemia
Tipo de estudo:
Clinical_trials
Limite:
Aged
/
Humans
Idioma:
En
Revista:
Heart Fail Clin
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Israel